Primary Outcome Measures
Relapse-free survival [Time Frame: 84 months] [Designated as safety issue: ]
Secondary Outcome Measures
Safety and tolerability assessed by incidence and severity of adverse events [Time Frame: 24 months] [Designated as safety issue: ]
Overall Survival (OS) [Time Frame: 84 months] [Designated as safety issue: ]
Non-relapse Mortality [Time Frame: 84 months] [Designated as safety issue: ]
Event-free Survival (EFS) at 12 months [Time Frame: 12 months] [Designated as safety issue: ]
Event-free Survival (EFS) at 24 months [Time Frame: 24 months] [Designated as safety issue: ]
Cumulative Incidence of Acute Graft vs. Host Disease (GVHD) [Time Frame: 6 months] [Designated as safety issue: ]
Cumulative Incidence of Chronic GVHD at 12 months [Time Frame: 12 months] [Designated as safety issue: ]
Cumulative Incidence of Chronic GVHD at 24 months [Time Frame: 24 months] [Designated as safety issue: ]
The cumulative incidence of detection of FLT3/ITD MRD [Time Frame: 24 months] [Designated as safety issue: ]
Incidence of Severity of Infection [Time Frame: 28 months] [Designated as safety issue: ]